US Stock MarketDetailed Quotes
ITOS ITeos Therapeutics
- 8.550
- +0.010+0.12%
Close Nov 29 13:00 ET
- 8.550
- 0.0000.00%
Post 17:01 ET
312.36MMarket Cap-2722P/E (TTM)
8.610High8.430Low125.01KVolume8.540Open8.540Pre Close1.07MTurnover0.44%Turnover RatioLossP/E (Static)36.53MShares18.75052wk High0.49P/B240.65MFloat Cap7.54052wk Low--Dividend TTM28.15MShs Float52.430Historical High--Div YieldTTM2.11%Amplitude7.540Historical Low8.536Avg Price1Lot Size
About ITeos Therapeutics Company
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.
Company Profile
SymbolITOS
Company NameITeos Therapeutics
Listing DateJul 24, 2020
Issue Price19.00
Founded2012
CEODr. Michel Detheux, PhD
MarketNASDAQ
Employees157
Fiscal Year Ends12-31
Address321 Arsenal Street
CityWatertown
ProvinceMassachusetts
CountryUnited States of America
Zip Code02472
Phone1-339-217-0162
Company Executives
- Name
- Position
- Salary
- Dr. Michel Detheux, PhD
- President, Chief Executive Officer and Director
- 10.51M
- Dr. Yvonne McGrath
- Chief Scientific Officer
- --
- Matthew Gall
- Chief Financial Officer and Principal Accounting Officer
- --
- Matthew Call
- Chief Operating Officer
- 2.86M
- David L. Hallal
- Chairman of the Board
- 403.46K
- David K. Lee
- Independent Director
- --
- Tim Van Hauwermeiren, M. Sc.
- Independent Director
- 295.46K
- Dr. Tony Ho, M.D.
- Independent Director
- 296.96K
- Dr. Robert Iannone, M.D.
- Independent Director
- 297.96K
- Ann D. Rhoads
- Independent Director
- 309.46K
- Jill DeSimone
- Independent Director
- --
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data